

Figure S1. Kaplan-Meier plots of the overall survival of patients with renal clear cell carcinoma, hepatocellular carcinoma and adrenocortical carcinoma stratified by the ZNF692 expression. KIRC, kidney renal clear cell carcinoma; LIHC, liver hepatocellular carcinoma; ACC, adrenocortical carcinoma.






Figure S2. ZNF692 is overexpressed in thirteen other malignancies in data available from the UALCAN. BLCA, bladder urothelial carcinoma; LUAD, lung adenocarcinoma; KIRC, kidney renal clear cell carcinoma; PRAD, prostate adenocarcinoma; LUSC, lung squamous cell carcinoma; HNSC, head and neck squamous cell carcinoma; KIRP, renal papillary cell carcinoma; ESCA; esophageal carcinoma; LIHC, liver hepatocellular carcinoma; READ, rectum adenocarcinoma; UCEC, uterine corpus endometrial carcinoma; CHOL, cholangiocarcinoma; STAD, stomach adenocarcinoma.




Figure S3. Western blotting validation of the effects of ZNF692 knockdown and overexpression on the expression of ERK1/2, p-ERK1/2, JNK and p-JNK in COAD cells. GAPDH was used as an endogenous control. ZNF692, zinc finger protein 692; ERK, extracellular signal-regulated kinase; p-, phosphorylated; JNK, c-Jun N-terminal kinase; sh-NC, negative control cells; sh-ZNF692, ZNF692-silenced cells; pcDNA ZNF692, ZNF692-overexpressing cells.

